Pharmacyclics Inc

Pharmacyclics — Technical Presentation (April 2013)

24 slides from Pharmacyclics's technical presentation, Apr 8, 2013

  1. Slide 1: Potent single agent activity of Ibrutinib (PCI-32765) in patients with CLL

    Potent single agent activity of Ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia (CLL): clinical and translational results from an ongoing phase Il study Adrian Wiestner, MD/PhD Hematology Branch, NHLBI, National Institutes of Health Bethesda, MD PLINS » National Heat Sans Lung an

  2. Slide 2: Disclosures: Adrian Wiestner

    Disclosures: Adrian Wiestner « Employee of the National Heart, Lung, and Blood Institute. + Supported by the Intramural Research Program, NHLBI, NIH. * Clinical trial of the investigational drug ibrutinib, provided by Pharmacyclics.

  3. Slide 3: Chronic Lymphocytic Leukemia

    Chronic Lymphocytic Leukemia Accumulation of mature clonal B-cells in CLL: >5,000 clonal B-lymphocytes/uL of blood, CD19+, CD5+, CD23+, CD20 dim, FMC7 negative Small Lymphocytic Lymophoma (SLL): same biology, <5,000 clonal B-lymphocytes/uL of blood

  4. Slide 4: Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab

    Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab Less effective for CLLwith deletion of 17p (del 17p). Overall Survival (%) *) on Less tolerable in 204 Hegingle elderly / frail 10} Na upnigietgiag patients. = Sob bh bk oo hm & Time since randomisation (months) Halle

  5. Slide 5: B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL

    B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL Antigen GRO @ YZ SZ cpD79 extracellular intracellular Proliferation, Survival, Migration Modified from Wiestner, JCO 2013.

  6. Slide 6: BCR signaling is activated in the lymph node

    BCR signaling is activated in the lymph node Activation of SYK kinase Upregulation of BCR downstream of the BCR target genes Blood Bone Lymph Lymph node a“ aH marrow node # 2.5% wi 14.6% x 108 04] = o. of a ; . P va “. a 5 Te wee Te we 2 Herishanu, (...), Wiestner. Blood, 2011

  7. Slide 7: Ibrutinib, an irreversible inhibitor of BTK, disrupts BCR signaling

    Ibrutinib, an irreversible inhibitor of BTK, disrupts BCR signaling ~<— EY cD79 nf po extracetitutar intracellular Ibrutinib (PCI-32765) Modified from Wiestner, JCO 2013. aw

  8. Slide 8: Study design

    Study design (12-H-0035, Hematology, NHLBI) Ibrutinib 420 mg daily (28 day cycles) Off Treatment: Progressive Disease CLL/SLL up to 86 patients Response Continue . >65y old até Treatment 420 months me ally, 2. del17p Relapsed or treatment naive Blood and lymph node for correlative Off Treatment: Int

  9. Slide 9: Study population

    Study population Cohorts * >65,n =24, 8 treatment naive + Del 17p, n= 29, 15 treatment naive At6 months, n = 44 evaluable . Age 33-85 year 58% male 72% Rai stage 3-4 45% bulky disease (>5cm) 74% splenomegaly 12-H-0035, Hematology, NHLBI 9

  10. Slide 10: Safety and tolerability

    Safety and tolerability Most common adverse events (grade 1-2): diarrhea, rash, arthralgia, cramps, mouth sores, fatigue. Grade 23 non-hematologic AEs (13% of patients): infection, rash. Hematologic adverse events rare. No drug discontinuation for adverse events. Dose reductions for recurrent grade

  11. Slide 11: Response to ibrutinib at months

    Response to ibrutinib at 6 months 17p deletion (n=24) no 17p deletion (n=20) \ \p u PR (IWCLL) & PR (IWCLL) & PR with lymphocytosis & PR with lymphocytosis =PD (n=) §SD (n=1) 12-H-0035, Hematology, NHLBI 11

  12. Slide 12: Transient lymphocytosis on ibrutinib is not indicative of progression

    Transient lymphocytosis on ibrutinib is not indicative of progression All patients 300 Mean (+/- sem) } % of pre- 200) treatment ¢ ALC ¢ duringtreatment 1°] @ g .] 0 0 4 2 3004 5 6 At the completion of cycle 12-H-0035, Hematology, NHLBI 12

  13. Slide 13: Change in ALC on ibrutinib

    Change in ALC on ibrutinib % change in ALC at 6 months compared to pre-treatment decreased increased 0 = 00 ml ' -25 00 | 00 -50 00 SLL 00 -75 Ec 00 |00 ||| 12-H-0035, Hematology, NHLBI = oy wk a eN -100 13

  14. Slide 14: Lymph node response at months

    Lymph node response at 6 months 2 % decrease in SPD of lymph nodes — .5 at 6 months/ pre-treatment 7 -100 a 3 a 12-H-0035, Hematology, NHLBI 14

  15. Slide 15: Volumetric measurement of spleen response at months

    Volumetric measurement of spleen response at 6 months % decrease in spleen volume 0 | Al 8 Ss 6 3 -80 -100 12-H-0035, Hematology, NHLBI 15

  16. Slide 16: Bone marrow response at months

    Pretreatment At6 months Bone marrow response at 6 months % change in tumor burden 50 25 4 : Mh -100 — 12-H-0035, Hematology, NHLBI 16

  17. Slide 17: Responses to ibrutinib appear durable

    Responses to ibrutinib appear durable PFS probability 08 06 o4 02 0.0 a ‘| PDat 3 weeks presumed Richter’s PFS estimate at 12 months 94% Three events: transformation. Two deaths at day +3 and at 7 weeks. a 4 6 8 10 2 Months on Study 12-H-0035, Hematology, NHLBI 17

  18. Slide 18: Ibrutinib inhibits tumor proliferation in the lymph node

    Pre treatment At 2 months Ibrutinib inhibits tumor proliferation in the lymph node 5 £ 8 £ 2 a core biopsies 12-H-0035, Hematology, NHLBI 18

  19. Slide 19: Ibrutinib inhibits BCR signaling in CLL cells in the lymph node

    Ibrutinib inhibits BCR signaling in CLL cells in the lymph node €ccl4 Upregulation of BCR <EGRI Quantitative target genes in CLL = < KRG PCR i < cells in the lymph node. <€GFIt assay Herishanu, Blood 2011 Reduction in BCR target gene expression by ibrutinib (lymph node) 0 0 Relative gene 4 A express

  20. Slide 20: Rapid and sustained decrease in BCR and NF-κB target genes in circulating CLL cells

    Rapid and sustained decrease in BCR and NF- «B target genes in circulating CLL cells BCR target gene NF-«B target gene expression expression (in CD19+ purified cells) (in CD19+ purified cells) Relative expression onibrutinib / baseline (log2) Study day 12-H-0035, Hematology, NHLBI 20

  21. Slide 21: Decrease in PLCy2 activation by ibrutinib confirms on-target effect in vivo

    Decrease in PLCy2 activation by ibrutinib confirms on-target effect in vivo Phosphorylation of PLCy2 by flow cytometry of CLL cells in the blood 80 P<.001 —— %CLL 60 we cells pPLCy2 40 positive 20 0 Pre 12-H-0035, Hematology, NHLBI 21

  22. Slide 22: Downregulation of cellular activation and proliferation by ibrutinib

    Downregulation of cellular activation and proliferation by ibrutinib (CD69 on CLL cells in the blood) 60 % cD69 40 positive CLL cells 7° 0 Activation P<.001 —__ T- Pre Proliferation (Ki67 in CLL cells in the blood) 4 P< 001 % 3 Ki67 TT positive 2 CLL cells 4 ; | Pre Day 28 12-H-0035, Hematology, NHL

  23. Slide 23: Summary and Conclusions

    Summary and Conclusions Ibrutinib as a single agent is well tolerated and highly effective in CLL. — High response rates irrespective of 17p deletion. Responses appear durable. Rapid disease control in all anatomic sites. Rapid and sustained inhibition of BCR and NF-KB signaling in vivo confirm on t

  24. Slide 24: Supported by the Intramural Research Program of NHLBI/NIH

    Supported by the Intramural Research Program of NHLBI/NIH Our patients for participating Mohammed Farooqui Sarah Herman Georg Aue Nakhle Saba Janet Valdez Susan Soto Rashida Mustafa Jade Jones Andrew Lipsky Irina Maric Laboratory Medicine Stefania Pittaluga Diane Arthur Pathology Richard Cheng Franc

Pharmacyclics — Technical Presentation (April 2013) on 6ix